Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-includes/functions.php on line 6131

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-includes/functions.php on line 6131

Notice: Undefined offset: 0 in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-content/themes/cri/single.php on line 10

Notice: Trying to get property 'name' of non-object in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-content/themes/cri/single.php on line 10
CAR T Cell Therapy Surges Forward - Cancer Research Institute
stdClass Object ( [getLoginUrlResponse] => stdClass Object ( [JSESSIONID] => 2BB29AD8589A37DE26652EB24D89623B.app30109b [routing_id] => 00000000.app30109b [url] => https://give.cancerresearch.org/site/CRConsAPI;jsessionid=00000000.app30109b?NONCE_TOKEN=8A9AA0E0403886D89ACD06AD97DE79BF [token] => TKoN7buYOo4SeYw3OSVDTn1zPgioxADn1mSYSGOY-4mDthaWFUrGX0tZA537yVVCpWVoYw_5HEa5C_fiDEqDyHLoGR0QCPFjstZ6CLM ) ) test

Immune to Cancer: The CRI Blog

Subscribe

Share

CAR T Cell Therapy Surges Forward

Matthew Tontonoz

A new article published today in the New England Journal of Medicine summarizes the latest progress being made with an experimental immunotherapy that uses a patient’s own T cells as powerful weapons against cancer. The treatment, called chimeric antigen receptor (CAR) T cell therapy, is being developed at the University of Pennsylvania under the leadership of CRI Scientific Advisory Council member Carl H. June, M.D.

Emily WhiteheadA total of 30 children and adults with advanced acute lymphoblastic leukemia (ALL) received the immunotherapy, which targets a molecule on leukemia cells called CD19. Complete responses were seen in 27 of 30 patients (90%), with 23 patients surviving at least 6 months, and 19 remaining in complete remission.

The exciting results, which were featured in today’s New York Times, are the latest in a string of positive reports about a technique that is proving to be a lifesaving cure for some patients, including young Emily Whitehead (right), whose inspiring story we have featured previously.

In addition to work at Penn, the Cancer Research Institute is also funding research on CARs at Memorial Sloan Kettering Cancer Center, the Fred Hutchinson Cancer Center, and the University of California, San Francisco.

Read more:

This site is registered on wpml.org as a development site.